MAPRx strongly supports CMS’ proposal to permit coverage of anti-obesity medications to treat obesity for appropriate indications. AOMs are a critical component of the continuum of obesity care. Read our Comment Letter
... Read moreMAPx appreciates the opportunity to comment on specific provisions in the CY 2026 policy and technical changes to MA and Part D. Read the Comment Letter
... Read moreThe IRA enacted the most significant changes to Part D since its inception, and these reforms have major implications for Medicare beneficiaries. In this new paper, the MAPRx Coalition examines the potential impact of three of IRA's major Part D provisions.
Read more: Hope for the best, prepare for the worst: The... Read more
The MAPRx Coalition (MAPRx) appreciates the opportunity to provide the Centers for Medicare & Medicaid Services (CMS) with comments regarding the new model documents for the implementation of the Medicare Prescription Payment Plan (MPPP) program set to take effect for Contract Year (CY) 2025.
... Read moreThe MAPRx Coalition is pleased that CMS has made several important changes to the Part D Reporting Requirements, many of which the Coalition advocated for in our April 2 comments.
... Read moreThe MAPRx Coalition appreciates the opportunity to provide the Centers for Medicare & Medicaid Services (CMS) with comments regarding Medicare Part D plan sponsor data reporting requirements, as requested in the notice published in the Federal Register on February 2, 2024.
Highlights include:
• Part D plan reporting on beneficiaries likely to benefit from... Read more
We are eager to hear about your experiences with the Medicare prescription drug program. We would like to hear about both good and bad experiences that you have had selecting and signing up for a plan, getting your drugs, and paying for your drugs. The form below will allow you to write your story.
Thank you for taking the time to tell us your story.